Dare Bioscience Inc expected to post a loss of 53 cents a share - Earnings Preview

Dare Bioscience

28/03/2025 20:56

Dare Bioscience Inc DARE.OQ DARE.O is expected to show a fall in quarterly revenue when it reports  results on March 31 for the period ending December 31 2024

The San Diego California-based  company is expected to report a 26.3% decrease in revenue to $1.333 million from $1.81 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Dare Bioscience Inc is for a loss of 53 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Dare Bioscience Inc is $13.00​, above​ its last closing price of $2.89. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.76
-0.73
-0.55
Beat
25
Jun. 30 2024
-0.65
0.00
1.52
Beat
Mar. 31 2024
-0.72
-0.72
-0.84
Missed
-16.7​
Dec. 31 2023
-1.60
-1.18
-0.72
Beat
38.8
​​Sep. 30 2023
-1.16
-1.18
-1.08
Beat
8.2
Jun. 30 2023
-1.21
-1.18
-1.20
Missed
-1.7​
Mar. 31 2023
-1.22
-1.20
-1.08
Beat
10
Dec. 31 2022
-1.62
-1.64
-2.28
Missed
-39

This summary was machine generated March 28 at 20:56 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)